{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:55:12Z","timestamp":1793656512381,"version":"4.5.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.bbmt.2018.02.018","type":"journal-article","created":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T17:54:04Z","timestamp":1519926844000},"page":"1135-1141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3595-7596","authenticated-orcid":false,"given":"Karlo","family":"Perica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renier J.","family":"Brentjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2018.02.018_bib0010","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1146\/annurev-cancerbio-050216-034351","article-title":"Chimeric antigen receptors: a paradigm shift in immunotherapy","volume":"1","author":"Sadelain","year":"2017","journal-title":"Annu Rev Cancer Biol"},{"issue":"5796","key":"10.1016\/j.bbmt.2018.02.018_bib0015","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.bbmt.2018.02.018_bib0020","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","article-title":"Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2","volume":"86","author":"Rosenberg","year":"1994","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.bbmt.2018.02.018_bib0025","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.bbmt.2018.02.018_bib0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/PPO.0000000000000027","article-title":"The emergence of T-bodies\/CAR T cells","volume":"20","author":"Eshhar","year":"2014","journal-title":"Cancer J"},{"key":"10.1016\/j.bbmt.2018.02.018_bib0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/hum.1990.1.1-5","article-title":"Retrovirus packaging cells","volume":"14","author":"Miller","year":"1990","journal-title":"Hum Gene Ther"},{"issue":"6","key":"10.1016\/j.bbmt.2018.02.018_bib0040","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.bbmt.2018.02.018_bib0045","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"issue":"20","key":"10.1016\/j.bbmt.2018.02.018_bib0050","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bbmt.2018.02.018_bib0055","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.02.018_bib0060","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"355","key":"10.1016\/j.bbmt.2018.02.018_bib0185","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor\u2014modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"224","key":"10.1016\/j.bbmt.2018.02.018_bib0065","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.bbmt.2018.02.018_bib0070","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.bbmt.2018.02.018_bib0075","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bbmt.2018.02.018_bib0080","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.bbmt.2018.02.018_bib0085","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bbmt.2018.02.018_bib0090","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/trf.14003","article-title":"Autologous lymphapheresis for the production of chimeric antigen receptor T cells","volume":"57","author":"Allen","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.bbmt.2018.02.018_bib0095","first-page":"1976","article-title":"Receptors CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell","volume":"61","author":"Hombach","year":"2001","journal-title":"cancer Res"},{"issue":"21","key":"10.1016\/j.bbmt.2018.02.018_bib0100","article-title":"Distinct Signaling by Chimeric Antigen Receptors (CARs) containing CD28 signaling domain versus 4-1BB in primary human T cells","volume":"122","author":"Posey","year":"2013","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.bbmt.2018.02.018_bib0105","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/0008-5472.CAN-11-0422","article-title":"In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)","volume":"71","author":"Song","year":"2011","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.bbmt.2018.02.018_bib0110","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbmt.2018.02.018_bib0115","article-title":"Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T-cell malignancies","author":"Mamonkin","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"10.1016\/j.bbmt.2018.02.018_bib0120","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.bbmt.2018.02.018_bib0125","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.bbmt.2018.02.018_bib0130","author":"Buechner"},{"key":"10.1016\/j.bbmt.2018.02.018_bib0135","author":"Schuster"},{"key":"10.1016\/j.bbmt.2018.02.018_bib0140","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.bbmt.2018.02.018_bib0145","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bbmt.2018.02.018_bib0150","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40425-017-0239-0","article-title":"The why, what, and how of the new FACT standards for immune effector cells","volume":"5","author":"Maus","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bbmt.2018.02.018_bib0155","author":"Foundation for the Accreditation of Cellular Therapy"},{"key":"10.1016\/j.bbmt.2018.02.018_bib0160","author":"Foundation for the Accreditation of Cellular Therapy"},{"issue":"16015","key":"10.1016\/j.bbmt.2018.02.018_bib0165","first-page":"1","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol Ther Oncolytics"},{"issue":"4","key":"10.1016\/j.bbmt.2018.02.018_bib0175","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.bbmt.2018.02.018_bib0180","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy","volume":"26","author":"Klebanoff","year":"2005","journal-title":"Trends Immunol"},{"issue":"177","key":"10.1016\/j.bbmt.2018.02.018_bib0190","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.bbmt.2018.02.018_bib0195","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.02.018_bib0200","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","author":"Neelapu","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"10.1016\/j.bbmt.2018.02.018_bib0215","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.bbmt.2018.02.018_bib0220","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bbmt.2018.02.018_bib9000","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.02.018_bib0230","author":"Park"},{"key":"10.1016\/j.bbmt.2018.02.018_bib0235","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy","author":"Hill","year":"2017","journal-title":"Blood"},{"issue":"303","key":"10.1016\/j.bbmt.2018.02.018_bib0225","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.bbmt.2018.02.018_bib0240","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"17","key":"10.1016\/j.bbmt.2018.02.018_bib0245","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.bbmt.2018.02.018_bib0250","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.2803.2803","article-title":"Minimal residual disease negative complete remissions following anti-CD22 Chimeric Antigen Receptor (CAR) in children and young adults with relapsed\/refractory Acute Lymphoblastic Leukemia (ALL)","volume":"128","author":"Shah","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.02.018_bib0255","first-page":"nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","author":"Fry","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.bbmt.2018.02.018_bib0260","first-page":"0","article-title":"FDA approval of tisagenlecleucel: promise and complexities of a $475 000 Cancer Drug","volume":"10017","author":"Bach","year":"2017","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.bbmt.2018.02.018_bib0265","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.bbmt.2017.06.017","article-title":"Real-world economic burden associated with transplant related complications","volume":"23","author":"Perales","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5644","key":"10.1016\/j.bbmt.2018.02.018_bib0270","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bbmt.2018.02.018_bib0275","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/mt.2009.16","article-title":"Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells","volume":"17","author":"Wang","year":"2009","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.bbmt.2018.02.018_bib0280","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12185-016-2039-6","article-title":"Biology and clinical application of CAR T cells for B cell malignancies","volume":"104","author":"Davila","year":"2016","journal-title":"Int J Hematol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118301046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118301046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:03:02Z","timestamp":1761058982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118301046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1083879118301046"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.02.018","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}